Kura Oncology to Report Second Quarter 2022 Financial Results
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
Clinical Trial
Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline
Enrollment remains on pace for Reviva’s Phase 3 clinical trial for the treatment of schizophrenia at 15 sites across the...
vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer
HIGH POINT, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused...
Paradise Medspa and Wellness Launch Groundbreaking Laser Acne Treatment AviClear
Phoenix, July 26, 2022 (GLOBE NEWSWIRE) -- Paradise Medspa and Wellness has been the Valley’s leader in aesthetic and wellnesses...
Healthy Extracts Launches New Clinical Study Investigating UBN ACTIVATE™ Effect on Golfers’ Energy, Focus and Scores
Golf Performance Study Golfer undergoing V02 max profile to establish their basic aerobic fitness. ACTUAL EEG BRAIN SCAN BEFORE &...
Predictive Oncology Strengthens Business with Appointment of a Chief Scientific Officer and Consolidation and Expansion of its Research and Development Arm
Julia Kirshner, Ph.D. Predictive Oncology Appoints Julia Kirshner, Ph.D., as Chief Scientific OfficerEAGAN, Minn., July 26, 2022 (GLOBE NEWSWIRE) --...
SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)
AURELIO-04 will enroll up to 320 patients and test the combination in multiple solid tumor indicationsClinical collaborator, MSD (Merck &...
TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a...
ORYZON Collaborates with the CMT Research Foundation in the US
To explore Oryzon’s HDAC6 inhibitors on Charcot-Marie-Tooth diseaseCMTRF to provide funding for in vivo efficacy tests in CMT preclinical modelMADRID...
COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022
LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating...
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH ZUG, Switzerland, July 26, 2022 – MoonLake Immunotherapeutics...
AGTC Receives Positive Type C Meeting Feedback from the FDA for the Company’s Design and Operating Procedures of its Planned cGMP Manufacturing Facility
— FDA feedback marks a key milestone in the construction of the facility expected to support AGTC’s pipeline, including the...
Aquestive Therapeutics to Participate in Wedbush PacGrow Healthcare Conference
WARREN, N.J., July 26, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve...
Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024
NORCROSS, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins,...
Sun Genomics and NZMP Expand Partnership to Uncover Added Health Benefits of Precision Probiotics
Building on a Successful Pilot Study, the Two Companies are Further Validating the Link Between Gut Health and HappinessSAN DIEGO...
CinCor Pharma Announces Last Patient Randomized in Phase 2 HALO Trial and Initiation of Long-Term Extension Study for Baxdrostat, a Selective Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension
Open Label Extension Study Will Evaluate Baxdrostat for Up to 52 Weeks Topline Data for Phase 2 HALO Trial Expected...
U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation
Key U.S. patent protection on injectable delivery of DMT in lead programs SPL026 and SPL028 LONDON, July 26, 2022 (GLOBE...
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads...
Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...
Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting
JERUSALEM, July 26, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the...